このページの翻訳は実験的なもので、現在開発中です。お待ちしております

OncoSil Medical マネジメント

マネジメント基準チェック /14

OncoSil Medical'sの CEO はNigel Langeで、 Jan2021年に任命され、の在任期間は 3.5年です。の年間総報酬はA$ 638.57Kで、 60.8%給与と39.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.22%を直接所有しており、その価値はA$ 43.31K 。経営陣と取締役会の平均在任期間はそれぞれ3.4年と1年です。

主要情報

Nigel Lange

最高経営責任者

AU$638.6k

報酬総額

CEO給与比率	60.8%
CEO在任期間	3.7yrs
CEOの所有権	0.2%
経営陣の平均在職期間	3.6yrs
取締役会の平均在任期間	1.1yrs

経営陣の近況

Recent updates

How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?

Dec 04

CEO報酬分析

OncoSil Medical の収益と比較して、Nigel Lange の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-AU$12m
Mar 31 2024	n/a	n/a	-AU$12m
Dec 31 2023	n/a	n/a	-AU$12m
Sep 30 2023	n/a	n/a	-AU$12m
Jun 30 2023	AU$639k	AU$388k	-AU$11m
Mar 31 2023	n/a	n/a	-AU$11m
Dec 31 2022	n/a	n/a	-AU$11m
Sep 30 2022	n/a	n/a	-AU$11m
Jun 30 2022	AU$608k	AU$388k	-AU$11m
Mar 31 2022	n/a	n/a	-AU$11m
Dec 31 2021	n/a	n/a	-AU$11m
Sep 30 2021	n/a	n/a	-AU$11m
Jun 30 2021	AU$964k	AU$359k	-AU$10m

報酬と市場: Nigelの総報酬 ($USD 430.02K ) は、 Australian市場 ($USD 300.74K ) の同規模の企業の平均を上回っています。

報酬と収益: Nigelの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Nigel Lange

3.7yrs

在職期間

AU$638,572

報酬

Mr. Nigel Lange serves as Chief Executive officer, Managing Director and Director of OncoSil Medical Limited since January 21, 2021. He served as President of EMEA at OncoSil Medical Limited since May 2020...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Nigel Lange	CEO, MD & Director	3.7yrs	AU$638.57k	0.19% A$ 101.1k
Christian Dal Cin	CFO & Company Secretary	1.3yrs	データなし	データなし
Ralph Peters	Chief Medical Officer	3.6yrs	データなし	データなし
David Turner	Head of Medical Affairs	3.6yrs	データなし	データなし

3.6yrs

平均在職期間

経験豊富な経営陣: OSLの経営陣は経験豊富であると考えられます ( 3.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Nigel Lange	CEO, MD & Director	3.7yrs	AU$638.57k	0.19% A$ 101.1k
Peter Hall	Non-Executive Director	less than a year	データなし	データなし
Douglas Cubbin	Chairman of the Board	1.1yrs	データなし	データなし
Gabriel Liberatore	Non-Executive Director	1.2yrs	データなし	データなし

1.1yrs

平均在職期間

経験豊富なボード: OSLの取締役会は経験豊富ではない ( 1年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

OncoSil Medical マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

OncoSil Medical Limited Appoints Peter Hall as Non-Executive Director

Oncosil Medical Limited Elects Gabrielle Liberatore as Director

OncoSil Medical Limited, Annual General Meeting, Nov 29, 2023

OncoSil Appoints Gabriel Liberatore to the Board

OncoSil Medical Limited Announces Appointment of Dal Cin as Chief Financial Officer

Oncosil Medical Ltd Announces Resignation of Karl Pechmann as Chief Financial Officer

Recent updates

Full year 2024 earnings released: AU$0.006 loss per share (vs AU$0.01 loss in FY 2023)

OncoSil Medical Limited Appoints Peter Hall as Non-Executive Director

OncoSil Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 2.7 million.

New major risk - Market cap size

OncoSil Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 1.48 million.

New major risk - Market cap size

Oncosil Medical Limited Elects Gabrielle Liberatore as Director

New major risk - Market cap size

New major risk - Share price stability

OncoSil Medical Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.013 loss in FY 2022)

OncoSil Appoints Gabriel Liberatore to the Board

OncoSil Medical Limited Announces Appointment of Dal Cin as Chief Financial Officer

Oncosil Medical Ltd Announces Resignation of Karl Pechmann as Chief Financial Officer

Insider recently bought AU$1.2m worth of stock

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.007 loss in 1H 2022)

Oncosil Medical Limited Announces Two Key Treatment Centres Treat First Patients with Oncosil

OncoSil Medical Limited has completed a Follow-on Equity Offering in the amount of AUD 6.09495 million.

Forecast to breakeven in 2025

Less than half of directors are independent

OncoSil Medical Limited Announces Resignation of Martin Cross as Director

OncoSil Medical Ltd Appoints Brian Leedman to the Board as a Non-Executive Director

Forecast to breakeven in 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

OncoSil Medical Limited, Annual General Meeting, Oct 25, 2022

Oncosil Medical Ltd Announces Second Patient Treated in Spain Proceeds to Successful Resection

Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky

Less than half of directors are independent

OncoSil Medical Ltd. Announces the First Commercial Treatment of the OncoSilTM Device in Europe

OncoSil Medical Limited Announces Fully-Funded Trial Approval in Germany To Increase Sales of OncoSil Device

Price target increased to AU$0.17

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Watching OncoSil Medical's (ASX:OSL) Cash Burn Situation

Oncosil Medical Limited announces PanCO Clinical Study on OncoSil(TM) Published in ESMO Open

Less than half of directors are independent

Is OncoSil Medical (ASX:OSL) In A Good Position To Deliver On Growth Plans?

Full year 2021 earnings released: AU$0.013 loss per share (vs AU$0.006 loss in FY 2020)

OncoSil Medical Limited Provides Update on TGA Regulatory

OncoSil Medical (ASX:OSL) Is In A Good Position To Deliver On Growth Plans

OncoSil Medical's (ASX:OSL) Stock Price Has Reduced 42% In The Past Five Years

Analysts lower revenue estimates to AU$189.0k

Price target lowered to AU$0.34

First half 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in 1H 2020)

OncoSil Medical Limited Announces Executive Appointments

We're Not Worried About OncoSil Medical's (ASX:OSL) Cash Burn

OncoSil Medical Limited Appoints Nigel Lange as Chief Executive Officer

How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?

OncoSil Medical Limited Announces Executive Changes

OncoSil Medical Limited Receives Swiss Regulatory Approval

Independent Non-Executive Chairman recently bought AU$405k worth of stock

Analysts update estimates

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

マネジメント基準チェック /14